Media

May 17 2023

Verismo Therapeutics Welcomes Sara Weiss as Senior Vice President of Clinical Operations

MORE >

May 2 2023

Verismo Therapeutics Announces the Activation of its STAR-101 Clinical Trial at the University of Pennsylvania

MORE >

April 13 2023

Verismo Therapeutics Presents STAR-101 Clinical Trial Design at the Annual Cholangiocarcinoma Foundation Conference

MORE >

April 5 2023

Verismo Therapeutics Secures Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110

MORE >

February 28 2023

Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor

MORE >

January 3 2023

Verismo Therapeutics Expands Quality and Compliance Team

MORE >

January 3 2023

Verismo Therapeutics Expands Quality and Compliance Team

MORE >

November 29 2022

Verismo Therapeutics Establishes R&D Center in Philadelphia to Drive KIR-CAR Platform Forward

MORE >

September 28 2022

Verismo Therapeutics Receives U.S. FDA Orphan Drug Designation for SynKIR™-110, a First-in-Class KIR-CAR T Cell Immunotherapy Candidate, for the Treatment of Mesothelioma

MORE >

September 20 2022

Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR™-110, a KIR-CAR T Cell Immunotherapy Candidate

MORE >